Francisca Sosa-Jurado

Dr. Francisca Sosa-Jurado

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Journal of Infection
Verified
Journal Article
Closed access
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
FSFrancisca Sosa-Jurado
Francisca Sosa-Jurado
VVVerónica Vallejo-Ruiz
Verónica Vallejo-Ruiz
DMDaniel Meléndez-Mena
Daniel Meléndez-Mena
JRJulio Reyes-Leyva
Julio Reyes-Leyva

2 June 2014 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
PDF file
VSVirginia SedenoMonge
Virginia SedenoMonge
RARaúl Arcega-Revilla
Raúl Arcega-Revilla
Emmanuel Rojas MoralesEmmanuel Rojas Morales
Emmanuel Rojas Morales
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
JPJuan Carlos Perez-García
Juan Carlos Perez-García
JRJulio Reyes-Leyva
Julio Reyes-Leyva

25 January 2010 in Virology Journal
Verified
Journal Article
Open access
PDF file
FSFrancisca Sosa-Jurado
Francisca Sosa-Jurado
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
BGBelinda Guzmán-Flores
Belinda Guzmán-Flores
JRJulia I Ruiz-Conde
Julia I Ruiz-Conde
DMDaniel Meléndez-Mena
Daniel Meléndez-Mena
JRJulio Reyes-Leyva
Julio Reyes-Leyva
Background: Worldwide, 130 million persons are estimated to be infected with HCV. Puebla is the Mexican state with the highest mortality due to hepatic cirrhosis. Therefore, it is imperative to obtain epidemiological data on HCV infection in asymptomatic people of this region. The objective of present study was to analyze the prevalence of antibodies and genotypes of hepatitis C virus (HCV) in blood donors from Puebla, Mexico. Results: The overall prevalence was 0.84% (515/61553). Distribution by region was: North, 0.86% (54/6270); Southeast, 1.04% (75/7197); Southwest, 0.93% (36/3852); and Central, 0.79% (350/44234). Ninety-six donors were enrolled for detection and genotyping of virus, from which 37 (38.5%) were HCV-RNA positive. Detected subtypes were: 1a (40.5%), 1b (27.0%), mixed 1a/1b (18.9%), undetermined genotype 1 (5.4%), 2a (2.7%), 2b (2.7%), and mixed 1a/2a (2.7%). All recovered donors with S/CO > 39 were HCV-RNA positive (11/11) and presented elevated ALT; in donors with S/CO < 39 HCV-RNA, positivity was of 30.4%; and 70% had normal values of ALT. The main risk factors associated with HCV infection were blood transfusion and surgery. Conclusions: HCV prevalence of donors in Puebla is similar to other Mexican states. The most prevalent genotype is 1, of which subtype 1a is the most frequent.

1 July 2003 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
FSFrancisca Sosa-Jurado
Francisca Sosa-Jurado
MMMiguel Mazariego-Aranda
Miguel Mazariego-Aranda
NHNidia Hernández-Becerril
Nidia Hernández-Becerril
VMVerónica Garza- Murillo
Verónica Garza- Murillo
MCManuel Cárdenas
Manuel Cárdenas
VMVictor M Monteón
Victor M Monteón
In México the first human chronic chagasic case was recognized in 1940. In spite of an increasing number of cases detected since that time, Chagas disease in México has been poorly documented. In the present work we studied 617 volunteers subjects living in high and low endemic regions of Trypanosoma cruzi infection with seroprevalence of 22% and 4% respectively. Hemoculture performed in those seropositive subjects failed to demonstrate circulating parasites, however polymerase chain reaction identified up to 60% of them as positives. A higher level of anti-T. cruzi antibodies was observed in seropositive residents in high endemic region, in spite of similar parasite persistence (p < 0.05). On standard 12 leads electrocardiogram (ECG) 20% to 22% seropositive individuals from either region showed right bundle branch block or ventricular extrasystoles which were more prevalent in seropositive than in seronegative individuals (p < 0.05). In conclusion, the frequency or type of ECG abnormality was influenced by serologic status but not by endemicity or parasite persistence. Furthermore, Mexican indeterminate patients have a similar ECG pattern to those reported in South America.

12 May 2016 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
MCMaría Elena Cárdenas-Perea
María Elena Cárdenas-Perea
EGEduardo Gómez-Conde
Eduardo Gómez-Conde
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
IPIrma Pérez-Contreras
Irma Pérez-Contreras
MDMaría Alicia Díaz-Orea
María Alicia Díaz-Orea
FSFrancisca Sosa-Jurado
Francisca Sosa-Jurado
Although preventable with vaccination, Hepatitis B virus (HBV) infection is a major health concern, with ∼400 million people at risk of developing the chronic form of the disease worldwide. The anti-HBV vaccine consists of a recombinant HBV surface antigen (HBsAg), which induces specific anti-HBs antibodies and confers 95% protection for >20 y. The aim of the present study was to analyze the response to HBV vaccination by measuring anti-HBs antibodies in serum samples from medical students of a public university in Puebla, Mexico. HBV infection markers HBsAg and anti-HBs, were also determined. A total of 201 students were included and vaccination coverage was found at 54%. Overall seropositivity for HBsAg, anti-HBc and anti-HBs determined by ELISA was 0.5%, 1.0% and 47%, respectively. Protective levels of anti-HBs >10 mIU/mL were found in 93.2% of subjects vaccinated with 2 or 3 doses and in 40% of those vaccinated with a single dose; while only 4.8% of unvaccinated subjects were anti-HBs positive. The response to the HBV vaccine was different in each participant, despite similar vaccination scheme. A history of blood transfusion/organ transplant or more than 2 sexual partners was significantly associated with anti-HBc positivity, OR = 399 (p = 0.010) and OR = 19.9 (p = 0.044), respectively. HBV immunization coverage was low in our sample compared with reports from countries with similar HBV prevalence, but anti-HBs in vaccinated individuals were in the expected range. It is important to promote HBV vaccination and awareness among medical students, due to their exposure risk.

10 February 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
FSFrancisca Sosa-Jurado
Francisca Sosa-Jurado
VHVerónica L Hernández-Galindo
Verónica L Hernández-Galindo
DMDaniel Meléndez-Mena
Daniel Meléndez-Mena
MMMiguel A Mendoza-Torres
Miguel A Mendoza-Torres
FMFernando J Martínez-Arroniz
Fernando J Martínez-Arroniz
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
Hepatitis C virus (HCV) is mainly transmitted by parenteral route, being blood transfusion and intravenous drug use the most frequent risk factors. However, it has been suggested that there are other routes of transmission. There are several studies where HCV RNA has been detected in saliva of patients infected with HCV, and epidemiological studies have proposed the dental treatments as possible risk factors for HCV transmission. The purpose of this study was to detect the presence of HCV RNA in saliva of patients with active infection and associating with periodontal or liver disease.